Solving the Problem of Insolubility: The Medicine Maker Interview Series (3-part)

In this three-part interview series with The Medicine Maker, AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine the growing challenge of poorly soluble drug candidates and what it means for modern drug development. As advances in AI-driven discovery, structure-based design, and in silico screening unlock increasingly complex molecules, formulation and manufacturing strategies must evolve to keep pace. The series explores the scientific roots of solubility challenges, the development and capabilities of KinetiSol™ technology, and how solvent-free processing can enable compounds that are difficult to formulate using conventional approaches. It also looks ahead to emerging applications for the technology and the expanding role of CDMOs in helping sponsors translate promising molecules into viable medicines.